Sy Jay C, Seshadri Gokulakrishnan, Yang Stephen C, Brown Milton, Oh Teresa, Dikalov Sergey, Murthy Niren, Davis Michael E
Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30322, USA.
Nat Mater. 2008 Nov;7(11):863-8. doi: 10.1038/nmat2299. Epub 2008 Oct 19.
Cardiac dysfunction following acute myocardial infarction is a major cause of death in the world and there is a compelling need for new therapeutic strategies. In this report we demonstrate that a direct cardiac injection of drug-loaded microparticles, formulated from the polymer poly(cyclohexane-1,4-diylacetone dimethylene ketal) (PCADK), improves cardiac function following myocardial infarction. Drug-delivery vehicles have great potential to improve the treatment of cardiac dysfunction by sustaining high concentrations of therapeutics within the damaged myocardium. PCADK is unique among currently used polymers in drug delivery in that its hydrolysis generates neutral degradation products. We show here that PCADK causes minimal tissue inflammatory response, thus enabling PCADK for the treatment of inflammatory diseases, such as cardiac dysfunction. PCADK holds great promise for treating myocardial infarction and other inflammatory diseases given its neutral, biocompatible degradation products and its ability to deliver a wide range of therapeutics.
急性心肌梗死后的心脏功能障碍是全球主要的死亡原因，因此迫切需要新的治疗策略。在本报告中，我们证明直接向心脏注射由聚合物聚（环己烷-1,4-二基亚丙酮二亚甲基缩酮）（PCADK）制成的载药微粒可改善心肌梗死后的心脏功能。药物递送载体通过在受损心肌内维持高浓度的治疗药物，具有改善心脏功能障碍治疗的巨大潜力。PCADK在目前用于药物递送的聚合物中是独特的，因为其水解产生中性降解产物。我们在此表明，PCADK引起的组织炎症反应最小，因此使PCADK可用于治疗炎症性疾病，如心脏功能障碍。鉴于其具有中性、生物相容性的降解产物以及递送多种治疗药物的能力，PCADK在治疗心肌梗死和其他炎症性疾病方面具有很大的前景。
